Physician profile
Youssef Nasr
NPI 1861756363
$2,639.21
in general payments reported to CMS, 2019-2025
19 companies · $558 in 2025
The $558 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $152 · 2021: $395 · 2022: $254 · 2023: $576 · 2024: $540 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $843.44 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $292.31 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $179.45 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.43 | 2023-2025 | Jardiance |
| Cvrx, INC. | $169.14 | 2023-2025 | Barostim Neo System |
| Pfizer INC. | $138.62 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $132.12 | 2023-2024 | Brilinta, Farxiga |
| Merck Sharp & Dohme LLC | $113.50 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $102.01 | 2023-2025 | Camzyos |
| Daiichi Sankyo INC. | $98.19 | 2023-2025 | Injectafer |
| Bridgebio Pharma, INC. | $97.33 | 2025 | Attruby |
| Medtronic, INC. | $93.85 | 2023 | Cobalt Dr Mri Surescan |
| Bayer Healthcare Pharmaceuticals INC. | $57.93 | 2024-2025 | |
| Edwards Lifesciences Corporation | $41.14 | 2025 | Sapien 3 Ultra Resilia |
| Alnylam Pharmaceuticals INC. | $38.54 | 2024 | Amvuttra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $28.97 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $14.96 | 2024 | |
| Novo Nordisk INC | $14.30 | 2024 | Rybelsus, Ozempic |
| Regeneron Healthcare Solutions, INC. | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Nasr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.